Phillip A. Sharp is an Institute Professor (highest academic rank) at the Massachusetts Institute of Technology and member of the Department of Biology and the Koch Institute for Integrative Cancer Research. He joined the Center for Cancer Research (now the Koch Institute) in 1974 and served as its director for six years, from 1985 to 1991, before taking over as head of the Department of Biology, a position he held for the next eight years. He was founding director of the McGovern Institute, a position he held from 2000 to 2004. His research interests have centered on the molecular biology of gene expression relevant to cancer and the mechanisms of RNA splicing.

His landmark work in 1977 provided the first indications of “discontinuous genes” in mammalian cells. The discovery fundamentally changed scientists’ understanding of gene structure and earned Sharp the 1993 Nobel Prize in Physiology or Medicine. Sharp has authored over 410 papers. He is an elected member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, the American Philosophical Society, and the Royal Society, UK. Among his many awards are the Gairdner Foundation International Award, the Lasker Basic Medical Research Award, and the National Medal of Science. His long list of service includes the presidency of the AAAS (2013) and Chair of the Scientific Advisory Committee of the SU2C Project, AACR. A native of Kentucky, Sharp earned a BA degree from Union College, Barbourville, KY, and a PhD in chemistry from the University of Illinois, Champaign-Urbana. Sharp is a co-founder of Biogen and Alnylam Pharmaceuticals Inc.

Elizabeth H. Blackburn is the Morris Herzstein Professor Emerita in the Department of Biochemistry and Biophysics at the University of California, San Francisco and President Emerita of the Salk Institute for Biological Studies. Blackburn earned a Bachelor of Science and a Master of Science at the University of Melbourne, Australia, and earned her PhD from the University of Cambridge in England. She went on to do her postdoctoral study in molecular and cellular biology at Yale University, and in 1978 joined the faculty of the University of California, Berkeley in the Department of Molecular Biology. In 1990, she moved to the Department of Microbiology and Immunology at University of California, San Francisco (UCSF), where she served as Department Chair from 1993 to 1999.

For the majority of her career, Blackburn has been investigating the structure and roles of telomeres. Her pioneering and innovative research has included the development of an anti-cancer therapy that forces cells with active telomerase to make errors during telomere synthesis, effectively triggering cellular suicide. More recently, she has been applying her insights into telomere biology toward understanding the life experiences and social influences that affect human telomeres and associated disease risks, including cancer risks and progression. One goal is to modulate telomere biology in healthy and at-risk people to reduce such risks.

Throughout her career, Blackburn has been recognized with many prestigious awards, including the 2009 Nobel Prize in Physiology or Medicine, the Lasker Award, AACR-Pezcoller Foundation International Award for Cancer Research, General Motors Cancer Research Foundation Alfred P. Sloan Award, AACR-G.H.A. Clowes Memorial Award, American Cancer Society Medal of Honor, 26th Annual Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research, Albany Medical Center Prize in Medicine and Biomedical Research, the Eli Lilly Research Award for Microbiology and Immunology, the National Academy of Science Award in Molecular Biology, the Australia Prize, the Harvey Prize, the Keio Prize, E.B.Wilson Award of the American Society for Cell Biology, and the Dr. A.H. Heineken Prize for Medicine. She was named California Scientist of the Year in 1999, and one of TIME Magazine’s 100 Most Influential People in 2007. She has received honorary degrees from several major universities. She served as the 1998 President of the American Society for Cell Biology, and the 2010-11 President of the American Association for Cancer Research. Blackburn is an elected Fellow of the National Academy of Sciences, the Academy of Medicine, the American Academy of Arts and Sciences, the Royal Society of London, the American Academy of Microbiology, the American Philosophical Society and the American Association for the Advancement of Science.

Raymond N. DuBois, MD, PhD, is an internationally renowned expert for his studies on the molecular and genetic basis for colorectal cancer. His laboratory examines the molecular mechanisms by which inflammation and inflammatory mediators affect tumor development and serve as targets for cancer prevention.

DuBois was named Dean of the College of Medicine at the Medical University of South Carolina (MUSC) in March 2016. Prior to his role as Dean, DuBois served as the Executive Director of the Biodesign Institute at Arizona State University with a joint appointment as Professor of Medicine in the Mayo College of Medicine. Before that (2007-2012) he served as the Provost and Executive Vice President at The University of Texas MD Anderson Cancer Center in Houston. Previously he directed Vanderbilt’s Division of Gastroenterology, Hepatology and Nutrition, and served as Director of the Vanderbilt-Ingram Cancer Center.

DuBois is an internationally renowned cancer researcher and leader in the cancer community. He is known for elucidating a key role of prostaglandins (PGs) and other inflammatory mediators in colorectal cancer, which facilitated clinical trials targeting this pathway in humans for cancer prevention. His work also confirmed the existence of a novel tumor suppressor gene in the PG pathway (15-PGDH) in colon cancer which is responsible for inactivation of PGE2. His research revealed that prostaglandins in the tumor microenvironment increase immune tolerance and resistance to therapy.

DuBois a Fellow of the American Association for the Advancement of Science and the American Association for Cancer Research (AACR) Academy, Past President of the AACR, the Southern Society for Clinical Investigation, and the International Society for Gastrointestinal Cancer. He was also inducted as a member of the American Clinical and Climatological Association, the Royal College of Physicians in London, the Association of American Physicians and the American Society for Clinical Investigation. He also currently serves on the AACR Academy leadership council.

During his career as a physician-scientist, DuBois has published over 150 peer reviewed research articles, more than 60 review articles, 25 book chapters, and three books. His work has been cited over 55,000 times as of 2018 according to Google Scholar. He is a co-inventor of a method to identify and prevent cellular genes needed for viral growth and cellular genes that function as tumor suppressors in mammals. His research has been continuously funded from the NIH and other agencies/foundations for the past 25 years.

DuBois earned a bachelor’s degree from Texas A&M University and a doctoral degree from The University of Texas Southwestern Medical Center in Dallas. He obtained a medical degree from The University of Texas School of Medicine in San Antonio, followed by an Osler Medicine internship and residency, and a gastroenterology fellowship at the Johns Hopkins Hospital in Baltimore.

Lee J. Helman, MD, is professor of Pediatrics and Medicine in the Keck School of Medicine, USC; head of Basic and Translational Research at the Children’s Center for Cancer and Blood Diseases, Children’s Hospital of Los Angeles and director of its Cancer Research Program.

Lee J. Helman received his MD from the University of Maryland School of Medicine magna cum laude and was elected to Alpha Omega Alpha. He completed his internship and residency in internal medicine at Barnes Hospital, Washington University. Helman completed training in medical oncology at the National Cancer Institute (NCI). He did his post-doctoral training in the Molecular Genetics Section, Pediatric Branch, NCI, and then became Head of the Molecular Oncology Section, Pediatric Oncology Branch, NCI. He served as Chief of the Pediatric Oncology Branch from 1997-2007 and as Scientific Director for Clinical Research in the Center for Cancer Research, NCI, from 2007 to 2016. He joined Children’s Hospital Los Angeles (CHLA) and the University of Southern California (USC) in 2017 as professor of Pediatrics and Medicine at the Keck School of Medicine and director of Basic and Translational Research within the Children’s Center for Cancer and Blood Diseases at CHLA and is a member of the USC Norris Comprehensive Cancer Center. He was elected to the American Society for Clinical Investigation and the American Association of Physicians and is a founding member and past president of the Connective Tissue Oncology Society. He received the 2011 ASCO Pediatric Oncology Award and is a Fellow of ASCO. Helman was the inaugural chair of the Pediatric Oncology Working Group of AACR. He serves as a vice chair of the Scientific Advisory Committee of Stand Up To Cancer, a scientific partner to the AACR. Helman’s laboratory work focuses on the biology and treatment of rhabdomyosarcoma, Ewing’s sarcoma, osteosarcoma, and pediatric GIST tumors. Major areas of research include the pathophysiologic consequences of IGF signaling, identification of the molecular/biochemical determinants of the biology of sarcomas, and the application of functional genomics to identify new treatment targets.

Arnold Levine is a leader in cancer research. In 1979, Levine was one of the co-discoverers of the p53 protein. The p53 gene and its protein are central players in our present day understanding of cancers. This discovery has generated more than 60,000 publications. In 1989, Levine’s group demonstrated that the wild type p53 gene and protein functioned as a tumor suppressor, preventing transformation by oncogenes. This observation changed the direction of the field.

The research paths of the Levine group provide clear evidence that the p53 pathway plays a central role in the prevention of human cancers and that polymorphic variations in components of the pathway can influence individual responses to environmental mutagens, age of cancer onset, sexual dimorphisms in cancers, response to therapy and survival times, all for a gene whose mutations cause the most common genetic alterations in cancers. This research helped to uncover the genetic origins of cancer and focus drug discovery on a rational path to treat cancers.

William G. Nelson, MD, PhD, is the Marion I. Knott Director and Professor of Oncology and Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, MD. Nelson directs a translational research laboratory focused on discovering new strategies for prostate cancer treatment and prevention and manages a clinical practice focused on developing these new treatment and prevention approaches in early “proof-of-principle” prostate clinical trials.

Nelson is a recognized leader in translational cancer research. He was one of three co-chairs of the National Cancer Institute’s Translational Research Working Group, which worked to re-engineer translational cancer science across the nation.

Adams has more than 30 years of experience in drug discovery and development with a strong focus on cancer research. In 2018 Adams joined Gamida Cell as CEO and Chairman, and serves Clal Biotechnology Industries as its Scientific Advisor. He was previously Chief Scientific Officer and President of Research and Development at Infinity Pharmaceuticals. Prior to joining Infinity in 2003, Adams was the senior vice president of drug discovery and development at Millennium Pharmaceuticals, where he headed multiple global drug discovery and development programs, including the successful Velcade® (bortezomib) program. Adams also held senior positions in research and development at LeukoSite (acquired by Millennium) and at ProScript, as well as in medicinal chemistry at Boehringer Ingelheim, where he is credited with discovering Viramune® (nevirapine) for HIV.

Julian has received many awards, including the 2012 Warren Alpert Foundation Prize for his role in the discovery and development of bortezomib, the 2012 C. Chester Stock Award Lectureship from Memorial Sloan-Kettering Cancer Center, and the 2001 Ribbon of Hope Award for Velcade® from the International Myeloma Foundation. He is an inventor on more than 40 patents and has authored over 100 papers and book chapters in peer-reviewed journals.

Adams received his B.S. from McGill University and his PhD from the Massachusetts Institute of Technology. He also received a Doctor of Science, honoris causa, from McGill University in 2012.

Carlos L. Arteaga is the Director of the Harold C. Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs at UT Southwestern Medical Center.

Arteaga earned his medical degree at the University of Guayaquil in Ecuador. He trained in internal medicine and medical oncology at Emory University and the University of Texas Health Science Center at San Antonio. He joined Vanderbilt University Medical Center in 1989, where he held the Donna S. Hall Chair in Breast Cancer Research and served at the Vanderbilt-Ingram Cancer Center (VICC) as Director of the Center for Cancer Targeted Therapies, the Director of the Breast Cancer Program, and the Associate Director for Translational/Clinical Research until 2017, when he joined UT Southwestern.

Arteaga has more than 300 publications in the areas of oncogenes and breast tumor initiation and progression, development of targeted therapies and biomarkers of drug action and resistance, and investigator-initiated clinical trials in breast cancer. His research is or has been funded by the National Cancer Institute (NCI), CPRIT, the American Cancer Society, the Department of Defense Breast Cancer Research Program, Stand Up 2 Cancer (SU2C), and the Susan G. Komen for the Cure and Breast Cancer Research foundations.

During his career, Arteaga has received several awards, including the American Association for Cancer Research-Richard and Hinda Rosenthal Award, the American Cancer Society Clinical Research Professor Award, the Gianni Bonadonna Award from the American Society of Clinical Oncology, the Brinker Award for Scientific Distinction from the Susan G. Komen Foundation, the 2015 Prize for Scientific Excellence in Medicine from the American-Italian Cancer Foundation, and the Clinical Investigator Award from the U.S. Department of Veteran Affairs.

He is an elected Fellow of the American Association for the Advancement of Science, a Fellow of the American Association for Cancer Research Academy, an elected member of both the American Society for Clinical Investigation and the Association of American Physicians, and member of the Susan G. Komen Scientific Advisory Board. He also serves on the advisory boards.

Alan Bernstein is President of the Canadian Institute for Advanced Research (CIFAR), Canada’s global research institute. From 2008-2011, Bernstein was the executive director of the Global HIV Vaccine Enterprise, an international alliance of researchers and funders charged with accelerating the search for an HIV vaccine.

Previously, he served as the founding president of the Canadian Institutes of Health Research (2000-2007), Canada’s federal agency for the support of health research. In that capacity, he led the transformation of health research in Canada. After receiving his PhD from the University of Toronto, and following postdoctoral work in London, Bernstein joined the Ontario Cancer Institute (1974-1985). In 1985, he joined the new Samuel Lunenfeld Research Institute in Toronto, was named Associate Director in 1988 and then Director of Research (1994-2000).

Internationally known for his contributions to our understanding of the molecular basis of cancer, Bernstein has made extensive contributions to the study of stem cells, hematopoiesis and cancer. He chairs or is a member of advisory and review boards in Canada, the US, UK and Italy. Bernstein has received numerous awards and honourary degrees for his contributions to science, including the 2008 Gairdner Wightman Award, induction into the Canadian Medical Hall of Fame, and the Henry G. Friesen International Prize in Health Research. He is a Senior Research Fellow of Massey College, received the Order of Ontario in 2018 and was appointed an Officer of the Order of Canada in 2002.

John D. Carpten, PhD, currently serves as Professor and Chair for the Department of Translational Genomics, and Director of the Institute for Translational Genomics, the Keck School of Medicine, University of Southern California, Los Angeles, CA. Previously he was Professor and Deputy Director of Basic Sciences, Translational Genomics Research Institute, Phoenix, AZ.

Carpten’s research background spans a very broad range of topics including work in germline genetics, tumor genome analysis, cancer cell biology, and health disparities. His research program centers around the development and application of cutting edge genomic technologies and bioinformatics analysis in search of germ-line and somatic alterations that are associated with cancer risk and tumor biology, respectively. His work spans many of the known cancer types including but not limited to prostate cancer, breast cancer, colon cancer, brain cancer, multiple myeloma, and pediatric cancers.

Moreover, Carpten has an intense focus on understanding the role of biology in disparate cancer incidence and mortality rates seem among underrepresented populations. He was names a Science Trailblazer by Spectrum Magazine in 2006, and was awarded Susan G. Komen Distinguished Lectureship on the Science of Cancer Health Disparities in 2014 for his untiring work in ensuring that all people are equally represented in science and innovative healthcare. More recently, Carpten was awarded the Jane Cooke Wright Memorial Lectureship by Minorities in Cancer Research of the American Association for Cancer Research (AACR) for his outstanding work in cancer disparities and his efforts to develop the careers of minority scientists.

Carpten has participated in numerous evaluative positions throughout his career. He served as a Senior Editor for Cancer Research, a journal of the AACR, and as an ad hoc editor for a number of other high impact journals. He has served on and chaired several NIH study sections, and is currently a permanent member of the NCI Board of Scientific Counselors. He also sits on one of the NIH Director’s Special Advisory committees. He served as Program Committee Chairperson for the AACR 2019 Annual Meeting in Atlanta and co-chaired the AACR inaugural Special Conference on the Science of Cancer Health Disparities.

Richard Gaynor joined Neon Therapeutics in 2016 as President of Research and Development. Prior to joining Neon, Gaynor was Senior Vice President of global product development and medical affairs at Lilly Oncology. In total, he spent 15 years in senior roles at Lilly Oncology where he led preclinical and early clinical research, directed the biomarker and research groups, and served on key company portfolio review committees.

Gaynor began his career in academia, spending nine years on the faculty at UCLA School of Medicine followed by 11 years on the faculty at the University of Texas Southwestern Medical School, including serving as the Chief of the Division of Hematology-Oncology and Director of the Simmons Cancer Center. In 2002, he moved to Eli Lilly, where he began his industry career overseeing both oncology drug discovery and early clinical development. Gaynor chaired the Lilly Oncology Research and Development Committee and helped oversee a variety of collaborations, including with Bristol-Myers Squibb, Merck, AstraZeneca and GE. He is the author of nearly 150 publications and has served on numerous boards and committees, including several with the AACR, the Stand Up To Cancer Scientific Advisory Committee, the MD Anderson Moon Shots Advisory Board, the Damon Runyon Cancer Research Foundation and Accelerating Cancer Cures.

Gaynor holds an MD from the University of Texas Southwestern Medical School and, following his residency in internal medicine there, he completed fellowship training in hematology-oncology at the UCLA School of Medicine.

Nancy Goodman is Founder and Executive Director of Kids v Cancer, a nonprofit that was lead advocate and author of two Federal laws to incentivize and require pharmaceutical companies to develop drugs for children. The Creating Hope Act pediatric priority review voucher program, passed into law in 2012 as 12 U.S.C. 360ff, established a market-based incentive, a voucher, for companies to develop drugs expressly for children with pediatric rare diseases, including pediatric cancers. Over $1.2 billion in vouchers have been traded since the establishment of the program. The RACE for Children Act, which amends the Pediatric Research Equity Act (PREA), 21 U.S.C. 355c, was passed into law in 2017, authorizes the FDA to require companies developing cancer targeted therapies to undertake pediatric studies when the molecular targets of the drugs are substantially relevant to pediatric cancers.

Kids v Cancer was selected by Fast Company Magazine as top ten most innovative non-profits in 2016 and won the Peter Drucker Nonprofit Innovation Award in 2015. Nancy was awarded the Rare Disease Legislative Advocates Rare Disease Award and The One Hundred: top cancer leaders by Massachusetts General Hospital. She serves the National Cancer Institute Board of Scientific Counselors.

Nancy’s son, Jacob, died of a pediatric brain cancer when he was ten. Nancy is a graduate of the University of Chicago Law School, Harvard Kennedy School of Government and University of Pennsylvania.

William N. Hait is Global Head, Johnson & Johnson External Innovation, a unit that comprises Johnson & Johnson Innovation (Innovation Centers, J-Labs and the Johnson & Johnson Development Corporation), Johnson and Johnson Lung Cancer Initiative, and the World Without Disease Accelerator. In this role, he leads the mission to source innovation from wherever it originates, accelerate the filling of R&D pipelines in all of the J&J sectors, drive the creation of cross-sector R&D programs with a focus on prevention, interception and cures, and ensure the future by getting out ahead of potentially disruptive technologies.

Hait joined Johnson & Johnson in 2007 and was the Global Therapeutic Area Head, Oncology, from 2009 to 2011. He served as Global Head, Janssen R&D from 2011 through 2017.

Before joining J&J, he was the founding Director of The (Rutgers) Cancer Institute of New Jersey, which he led to receive the National Cancer Institute’s highest designation of Comprehensive Cancer Center in 2002. From 1993 to 2007 he was Professor of Medicine and Pharmacology and Associate Dean for Oncology Programs at the University of Medicine and Dentistry of New Jersey — Robert Wood Johnson Medical School.

After earning his B.A. from the University of Pennsylvania, Hait received his MD and PhD (Pharmacology) cum laude from the Medical College of Pennsylvania, where he was elected to Alpha Omega Alpha. He joined the Yale University School of Medicine faculty in 1984 and became Associate Professor of Medicine and Pharmacology, Chief of the Division of Medical Oncology, Associate Director of the Yale University Comprehensive Cancer Center, Director of the Breast Cancer Unit and Co-Director of the Lung Cancer Unit. Hait is Board Certified in Internal Medicine and Medical Oncology.

Hait devoted his time to numerous advisory and editorial boards. He was Editor-in-Chief of Clinical Cancer Research and Associate Editor of Cancer Research, served as President of the American Association for Cancer Research from 2007 – 2008 and currently serves as Treasurer. He has served on various committees for the American Association of Cancer Research (Chair, Clinical Cancer Research Committee), the American Society of Clinical Oncology, the Association of American Cancer Institutes (Board of Directors), the National Cancer Institute Board of Scientific Advisors and was founding Chairman of the Executive Management Committee of Stand Up to Cancer. He currently is a member of the Rutgers Cancer Institute of New Jersey Director’s Advisory Board, Board of External Advisors for the Dana Farber/Harvard Cancer Center, the Stand Up to Cancer Scientific Advisory Board, The Board of Directors of Research America! and the Vanderbilt University Biomedical Science Advisory Board.

Waun Ki Hong is the former head of the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center. Hong received his bachelor of science and medical degree from the Yon Sei University College of Engineering Science in Seoul, Korea. He went on to do his residency at the Boston Veterans Affairs Medical Center and became a Medical Oncology Fellow at the Memorial Sloan-Kettering Cancer Center in New York City. He joined MD Anderson in 1984 as chief of the Section of Head and Neck Medical Oncology and became chair of the Department of Thoracic/Head and Neck Medical Oncology in 1993.

Hong’s research interest includes retinoids, genetic predisposition to disease, biological markers, and chemoprevention, particularly the area of translational aerodigestive cancer research. His major research focus is working to identify and develop effective novel personalized molecularly targeted preventive and therapeutic approaches in patients with aerodigestive cancers and/or identify high-risk individuals to reduce incidence and mortality through an integrated translational research team effort.

Hong received the highly prestigious American Cancer Society Medal of Honor in Clinical Research and is an elected member of National Academy of Medicine. He was appointed to the National Cancer Advisory Board, and in 1996, became the first MD Anderson physician to receive an American Cancer Society Clinical Research Professorship, a lifetime honor presented in recognition of his distinguished career. In 2001-2002, he served as president of the American Association for Cancer Research. His many honors for outstanding achievements in clinical research and patient care include the AACR’s Joseph H. Burchenal and the Rosenthal Foundation Awards; and the American Society of Clinical Oncology’s most prestigious award, the David A. Karnofsky Award.

William G. Kaelin, Jr., is a Professor at the Dana-Farber Cancer Institute in Boston, MA. He received his medical degree from Duke University in 1982 and was a house officer in internal medicine at Johns Hopkins Hospital. He went on to become a medical oncology clinical fellow at the Dana-Farber Cancer Institute and a postdoctoral fellow in the laboratory of David Livingston, where he began his studies of tumor suppressor proteins. He became an independent investigator at Dana-Farber Cancer Institute in 1992 as a James S. McDonnell Scholar and became a Howard Hughes Medical Institute investigator in 1998. Kaelin is also a Professor in the Department of Medicine at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Senior Physician at Brigham and Women’s Hospital, and Associate Director for Basic Research at the Dana-Farber/Harvard Cancer Center.

Kaelin’s research interests have focused on tumor suppressor genes and the normal functions of the proteins they encode. The long-term goal of his work is to lay the foundation for the development of new anticancer therapies based on the functions of specific tumor suppressor proteins. His studies of tumor suppressor genes linked to hereditary forms of cancer have uncovered molecular pathways that are important in non-hereditary cancers and have accelerated the development of new treatments for kidney cancer.

Kaelin is an elected member of the Institute of Medicine and has served on numerous boards and committees, including the American Association for Cancer Research’s Board of Directors and the NCI Board of Scientific Advisors. He has received many awards for his work, including the AACR-Richard and Hinda Rosenthal Prize for Cancer Research and the Paul Marks Prize for Cancer Research from Memorial Sloan-Kettering Cancer.

Michael B. Kastan, MD, PhD, is the William and Jane Shingleton Professor of Pharmacology and Cancer Biology and Professor of Pediatrics at Duke University and serves as the Executive Director of the Duke Cancer Institute. He earned MD and PhD degrees from the Washington University School of Medicine and did his clinical training in Pediatrics and Pediatric Hematology-Oncology at Johns Hopkins. He was a Professor of Oncology, Pediatrics, and Molecular Biology at Johns Hopkins prior to becoming Chair of the Hematology-Oncology Department and later Cancer Center Director at St. Jude Children’s Research Hospital, before moving to Duke in 2011. He is a Pediatric Oncologist and a cancer biologist; his laboratory research concentrates on DNA damage and repair, tumor suppressor genes, and causes of cancer related to genetic predisposition and environmental exposures. His discoveries have made a major impact on our understanding of both how cancers develop and how they respond to chemotherapy and radiation therapy and his publications reporting the roles of p53 and ATM in DNA damage signaling are among the most highly cited publications in the biomedical literature of the past two decades. He has received numerous honors for his highly cited work, including election to the National Academy of Sciences, National Academy of Medicine, the American Academy of Arts and Sciences, and receiving the AACR-G.H.A. Clowes Memorial Award for outstanding contributions to basic cancer research. He has served as Chairman of the Board of Scientific Counselors of the National Cancer Institute (NCI), on the Boards of Directors of the American Association for Cancer Research (AACR) and the American Association of Cancer Institutes (AACI), as Editor-in-Chief of the journal Molecular Cancer Research, and as Editor of the textbook Clinical Oncology. He also serves on the scientific advisory board of the V Foundation.

Guillermina (Gigi) Lozano is professor and chair of the department of genetics at The University of Texas MD Anderson Cancer Center. She received her Bachelor of Science degree magna cum laude in biology and mathematics from the University of Texas Pan American and her doctorate in biochemistry from Rutgers University and the University of Medicine and Dentistry of New Jersey. After a short postdoctoral fellowship at Princeton University, she became a faculty member at The University of Texas MD Anderson Cancer Center where she has risen through the ranks.

Lozano directs a research laboratory that studies the p53 tumor suppressor pathway. Her contributions include the identification of the tumor suppressor p53 as a transcriptional activator and the finding that p53 missense mutations commonly observed in cancers were transcriptionally inactive. Using animal models, she has characterized the physiological importance of Mdm2 and Mdm4 proteins as critical inhibitors of p53 and the significance of various p53 mutations on tumorigenesis in vivo.

Lozano was elected a fellow of the American Association for the Advancement of Science in 2013. She was elected as a member of the National Academy of Medicine in 2014 and the National Academy of Science in 2017. She was honored with the Mattie Allen Fair Research Chair in 2004 from The University of Texas MD Anderson Cancer Center. In 2011, she received the Minorities in Cancer Research Jane Cooke Wright Lectureship from the American Association for Cancer Research. Lozano is also the recipient of distinguished alumni awards from both her undergraduate and graduate alma maters.

Tak W. Mak is the Director of the Campbell Family Institute for Breast Cancer Research at the Princess Margaret Cancer Centre in Toronto. He received a bachelor’s of science in biochemistry in 1967 and a master of science in biophysics in 1968 from the University of Wisconsin. He earned his PhD in Biochemistry from the University of Alberta in 1971. He is also senior scientist in the division of Stem Cell and Developmental Biology, Ontario Cancer Institute. Since 1984, he has been a Professor in the Departments of Medical Biophysics and Immunology at the University of Toronto.

Mak co-discovered the t-cell receptor, a key component of the immune system. His research is concentrated on gaining fundamental knowledge of the biology of cells in normal and disease settings, and in particular on the mechanisms underlying immune responses and tumorigenesis. His lab has initiated several complementary programs, many of which have evolved from the production and analysis of genetically engineered mouse strains.

Mak has received several awards and honors for his work. He is a member of the Order of Ontario and was elected as a foreign associate to the National Academy of Sciences in the discipline of immunology in 2002. Mak has received the King Faisal Prize for Medicine, the Gairdner Foundation International Award, the Paul Ehrlich Prize, the Novartis Prize in Immunology, the Killam Prize by the Canada Council for the Arts, and the Sloan Prize of the General Motors Cancer Foundation, and the Robert L. Noble Prize by the National Cancer Institute of Canada.

Andre Nussenzweig, PhD BIO Nussenzweig is an NIH Distinguished Investigator, and chief of the Laboratory of Genome Integrity at the National Institute of Health’s National Cancer Institute. Nussenzweig is a leading contributor to the study of mechanisms that maintain genomic stability and prevent cancer. His laboratory has elucidated many fundamental features of DNA damage and repair proteins and revealed the critical role they play in both normal and pathogenic states. His studies have emphasized the importance of DNA repair pathways as drivers of specific hematological malignancies and as contributors to chemo-resistance/sensitivity in breast and ovarian cancers. The goal of his program is to use hypothesis-driven approaches to develop therapeutic strategies in the treatment of cancers. Nussenzweig serves on multiple editorial boards and scientific advisory committees, including Stand Up To Cancer.

Roderic Ivan Pettigrew, PhD, MD, serves as CEO of Engineering Health (EnHealth) and executive dean for Engineering Medicine (EnMed) at Texas A&M and Houston Methodist Hospital. He was the founding Director of the US National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the NIH (2002-2017), oversaw $5 billion in research investments, and is credited with building it into the signature NIH institute for emerging medical technologies. Under Pettigrew’s leadership, NIBIB produced more patents per appropriated dollar than any other institute or federal agency. returning $30 per each $1 invested in research, or 3,000% (five times the already remarkable NIH average of 600%).

His newest undertaking is EnHealth, the world’s first initiative to holistically integrate engineering into all of the colleges of a university that are a part of the health care enterprise. EnMed is the first constituent initiative, creating a new school that integrates engineering into medical training to develop a new kind of engineering-minded physician who invents solutions to healthcare problems. An invention is required of each EnMed graduate, who will earn both MD and MEng degrees in four years.

Pettigrew’s expertise is in health technologies emerging from the convergence of the life sciences, the physical sciences, and engineering. An MIT graduate (PhD 1977) who finished his medical training at UCSD (1983), he is known internationally for his pioneering work involving four-dimensional imaging of the cardiovascular system using magnetic resonance (MRI). His current knowledge base also includes nanotechnology, regenerative medicine, and point-of-care technologies. He has been elected to membership in the National Academy of Medicine, the National Academy of Engineering, the National Academy of Inventors and the National Academy of Sciences, India. Other awards include the Pierre Galletti Award (highest honor) of the American Institute of Medical and Biological Engineering, the Inaugural Gold Medal of the Academy of Radiology Research, the Distinguished Service Medal of the International Society of Magnetic Resonance in Medicine, the Spirit of the Heart Award of the Association of Black Cardiologists, the Pritzker Distinguished Achievement Award of the Biomedical Engineering Society, and the Gold Medal of the Radiological Society of North America.

Cecil B. Pickett is the former President of Research and Development at Biogen Idec, having retired in 2009. Pickett earned his B.S. in biology from California State University at Hayward and his PhD in cell biology from University of California, Los Angeles. Previously, he served as Senior Vice President and President of Schering-Plough Research Institute, the pharmaceutical research arm of Schering-Plough Corporation. Pickett came to Schering-Plough Research Institute from Merck Research Laboratories, Montreal, Canada, and West Point, Pa., where he served as Senior Vice President of Basic Research. During his 15-years at Merck & Co., Pickett held various positions of increasing responsibility, including research fellow, biochemical regulation; associate director, department of molecular pharmacology and biochemistry; director, department of molecular pharmacology and biochemistry; executive director of research at the Merck Frosst Center for Therapeutic Research, Montreal; and vice president of the Center.

Pickett is an expert in drug development. During his career, he has overseen all aspects of the internal research and collaboration with partners aimed at developing, manufacturing, and marketing advanced drug therapies and has played an integral role in bringing several large and small molecule candidates into clinical development.

Pickett has published extensively in leading research journals and has been a frequent speaker at scientific symposia and conferences. He has received several major academic awards, appointments and fellowships and serves on a number of scientific committees and editorial boards of medical journals and research organizations. His awards and honors include the UCLA Alumni Association Award for Scholarly Achievement and Academic Distinction; the first Robert A. Scala Award and Lectureship in Toxicology of Rutgers University and the University of Medicine and Dentistry of New Jersey; and the CIIT Centers for Health Research Founders’ Award. Pickett served as a member of the U.S. Food and Drug Administration (FDA) Science Board, the Advisory Committee to the Director of the National Institutes of Health and The National Cancer Policy Board of the Institute of Medicine. He was elected to the Institute of Medicine of the National Academy of Sciences in 1993 and is also a member of The American Society for Cell Biology, American Society of Biochemistry & Molecular Biology, American Association for Cancer Research, and American Association for the Advancement of Science.

Arlene Sharpe, MD, PhD is the George Fabyan Professor of Comparative Pathology and Co-Chair of the Department of Microbiology and Immunobiology at Harvard Medical School. She is a member of the Department of Pathology at Brigham and Women’s Hospital, an Associate Member at the Broad Institute of MIT and Harvard, Leader of the Cancer Immunology Program at the Dana-Farber/Harvard Cancer Center, and Co-Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital.

Sharpe earned her A.B. from Harvard University and her MD and PhD degrees from Harvard Medical School. She completed residency training in Pathology at Brigham and Women’s Hospital and is board certified in Anatomic Pathology.

Sharpe is a leader in the field of T cell costimulation. Her laboratory has discovered and elucidated the functions of T cell costimulatory pathways, including the immunoinhibitory functions of the CTLA-4 and PD-1 pathways, which have become exceptionally promising targets for cancer immunotherapy. Her laboratory currently focuses on the roles of T cell costimulatory pathways in regulating T cell tolerance and effective antimicrobial and antitumor immunity, and translating fundamental understanding of T cell costimulation into new therapies for autoimmune diseases and cancer. Sharpe has published over 300 papers and was listed by Thomas Reuters as one of the most Highly Cited Researchers (top 1%) in 2014, 2015, 2017 and a 2016 Citation Laureate. She received the William B. Coley Award for Distinguished Research in Tumor immunology in 2014 and the Warren Alpert Foundation Prize in 2017 for her contributions to the discovery of PD-1 pathway.

Laura Shawver is president and chief executive officer of Synthorx, Inc utilizing synthetic biology to tune receptor pharmacology of cytokines and extend their half-life for immune-oncology and other serious diseases. She received her doctorate in pharmacology at the University of Iowa in 1984 and did postdoctoral training at the University of Virginia Cancer Center and the department of hematology and oncology at Washington University. Before joining Synthorx, Shawver was CEO of Cleave Biosciences and Phenomix Corporation. Previously, she was president of SUGEN Inc. which focused on kinases and their function in cancer growth and survival. Her work in understanding the role of VEGF receptor in tumor angiogenesis led to the development of a new class of drugs including SutentTM currently marketed by Pfizer for kidney and stomach cancer. Prior to her employment at SUGEN Inc., Shawver was employed at Berlex Biosciences (formerly Triton Biosciences). Diagnosed with ovarian cancer in 2006, she founded the non-profit organization, The Clearity Foundation which provides access to molecular profiling for women with recurrent and refractory disease to help prioritize treatment options. Shawver is an active member in the American Association for Cancer Research.

Ellen V. Sigal, PhD, is Chairperson and Founder of Friends of Cancer Research (Friends), a think tank and advocacy organization based in Washington, DC. Friends drives collaboration among partners from every healthcare sector to power advances in science, policy and regulation that speed life-saving treatments to patients. During the past 20 years, Friends has been instrumental in the creation and implementation of policies ensuring patients receive the best treatments in the fastest and safest way possible.
Sigal is Chair of the inaugural board of directors of the Reagan-Udall Foundation, a partnership designed to modernize medical product development, accelerate innovation and enhance product safety in collaboration with the U.S. Food and Drug Administration. She serves on the Board of the Foundation for the National Institutes of Health, where she chairs its Public Private Partnerships Committee.

In 2010, Sigal was appointed to a six-year term on the Board of Governors of the Patient Centered Outcomes Research Institute (PCORI) as a representative of patients and health consumers.

Additionally, in 2016 Sigal was named to Vice President Biden’s Cancer Moonshot Blue Ribbon Panel, to the Parker Institute for Immunotherapy Advisory Group and joined the inaugural board of advisors for the George Washington University’s Milken Institute of Public Health.

She also holds leadership positions with a broad range of cancer advocacy, public policy organizations and academic health centers including: MD Anderson Cancer Center External Advisory Board, the Duke University Cancer Center Board of Overseers, The Sidney Kimmel Comprehensive Cancer Center Advisory Council, and the Sylvester Comprehensive Cancer Center External Advisory Board.

David Tuveson completed chemistry at M.I.T., an MD-PhD at Johns Hopkins, medical residency at Brigham and Women’s Hospital and a medical oncology fellowship at Dana-Farber/Harvard. While training, Tuveson co-developed KIT inhibitors with George Demetri for gastrointestinal stromal tumors, and Kras-dependent mouse cancer models with Tyler Jacks. At the University of Pennsylvania his lab generated the first mouse models of ductal pancreatic cancer, and at the University of Cambridge they identified new therapies. At Cold Spring Harbor Laboratory they developed organoid models of pancreatic cancer with Hans Clevers, enabling basic discoveries and clinical findings including signatures of “common responders” to chemotherapy. Tuveson is professor and director of Cold Spring Harbor Cancer Center, the chief scientist of the Lustgarten Foundation for Pancreatic Cancer Research, Cancer Center Director and Roy J. Zuckerberg Professor at CSHL, and serves on the Board of Scientific Advisors of the NCI, the Scientific Advisory Committee of Stand Up To Cancer and the Board of Directors of AACR. Awards include the Rita Allen, Waldenstrom and Hamdan.

Alan Bernstein is President of the Canadian Institute for Advanced Research (CIFAR), Canada’s global research institute. From 2008-2011, Bernstein was the executive director of the Global HIV Vaccine Enterprise, an international alliance of researchers and funders charged with accelerating the search for an HIV vaccine.

Previously, he served as the founding president of the Canadian Institutes of Health Research (2000-2007), Canada’s federal agency for the support of health research. In that capacity, he led the transformation of health research in Canada. After receiving his Ph.D. from the University of Toronto, and following postdoctoral work in London, Bernstein joined the Ontario Cancer Institute (1974-1985). In 1985, he joined the new Samuel Lunenfeld Research Institute in Toronto, was named Associate Director in 1988 and then Director of Research (1994-2000).

Internationally known for his contributions to our understanding of the molecular basis of cancer, Bernstein has made extensive contributions to the study of stem cells, hematopoiesis and cancer. He chairs or is a member of advisory and review boards in Canada, the US, UK and Italy. Bernstein has received numerous awards and honourary degrees for his contributions to science, including the 2008 Gairdner Wightman Award, induction into the Canadian Medical Hall of Fame, and the Henry G. Friesen International Prize in Health Research. He is a Senior Research Fellow of Massey College, received the Order of Ontario in 2018 and was appointed an Officer of the Order of Canada in 2002.

A world leader of research in molecular biology and biochemistry, Phillip A. Sharp is Institute Professor at the Massachusetts Institute of Technology’s David H. Koch Institute for Integrative Cancer Research. His research has centered on the molecular biology of gene expression relevant to cancer and the mechanisms of RNA splicing.

His discovery in 1977 provided the first indications of “discontinuous genes” in mammalian cells and fundamentally changed scientists’ understanding of gene structure, earning Sharp the 1993 Nobel Prize in Physiology or Medicine. Sharp co-founded Biogen (now Biogen Idec), Alnylam Pharmaceuticals, an early-stage therapeutics company and Magen Biosciences Inc., a biotechnology company developing agents to promote the health of human skin.

Carlos L. Arteaga is the Director of the Harold C. Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs at UT Southwestern Medical Center.

Arteaga earned his medical degree at the University of Guayaquil in Ecuador. He trained in internal medicine and medical oncology at Emory University and the University of Texas Health Science Center at San Antonio. He joined Vanderbilt University Medical Center in 1989, where he held the Donna S. Hall Chair in Breast Cancer Research and served at the Vanderbilt-Ingram Cancer Center (VICC) as Director of the Center for Cancer Targeted Therapies, the Director of the Breast Cancer Program, and the Associate Director for Translational/Clinical Research until 2017, when he joined UT Southwestern.

Arteaga has more than 300 publications in the areas of oncogenes and breast tumor initiation and progression, development of targeted therapies and biomarkers of drug action and resistance, and investigator-initiated clinical trials in breast cancer. His research is or has been funded by the National Cancer Institute (NCI), CPRIT, the American Cancer Society, the Department of Defense Breast Cancer Research Program, Stand Up 2 Cancer (SU2C), and the Susan G. Komen for the Cure and Breast Cancer Research foundations.

During his career, Arteaga has received several awards, including the American Association for Cancer Research-Richard and Hinda Rosenthal Award, the American Cancer Society Clinical Research Professor Award, the Gianni Bonadonna Award from the American Society of Clinical Oncology, the Brinker Award for Scientific Distinction from the Susan G. Komen Foundation, the 2015 Prize for Scientific Excellence in Medicine from the American-Italian Cancer Foundation, and the Clinical Investigator Award from the U.S. Department of Veteran Affairs.

He is an elected Fellow of the American Association for the Advancement of Science, a Fellow of the American Association for Cancer Research Academy, an elected member of both the American Society for Clinical Investigation and the Association of American Physicians, and member of the Susan G. Komen Scientific Advisory Board. He also serves on the advisory boards.

Jenny C. Chang is Director of the Cancer Center at Houston Methodist Hospital in Houston, Texas, and Professor at Weill Cornell Medical School. She obtained her medical degree at Cambridge University in England, and then completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research in the United Kingdom. She was also awarded a research doctorate from the University of London. Her recent work has focused on the intrinsic therapy resistance of cancer stem cells (CSCs), which has led to several publications and international presentations. In addition, she has been awarded several federal grants to evaluate novel biologic agents, and holds patents on new technologic advances and therapeutic agents.

Chang has worked in the field of cancer stem cells for more than ten years. After her discovery that CSCs are chemo-resistant, and that targeting the EGFR/HER2 pathway can decrease this subpopulation, Chang has played a key role in demonstrating some of the limitations and mechanisms of CSCs (Creighton et al., 2009; Li et al., 2008). Her work is now focused on the mechanisms that regulate CSCs, as well as initiating and planning clinical trials that target this critical tumor initiating subpopulation. She is also interested in characterizing the cross-talk between these different pathways that may lead to mechanisms of resistance, and has identified some of the chief regulatory pathways, including inducible nitric oxide (iNOS) and JAK/STAT3 signaling involved in CSC self-renewal (Dave et al., 2014; Dave et al., 2017). She is a world-renown clinical investigator, credited as one of the first to describe intrinsic chemo-resistance of CSCs.

Carol Prives is the DaCosta Professor of Biological Sciences at Columbia University. She was educated in Canada, receiving her BSc and PhD from McGill University. After postdoctoral training at Albert Einstein College of Medicine and the Weizmann Institute, she became a faculty member at the Weizmann, after which she joined the Biological Sciences Department at Columbia University where she was appointed to a named professorship in 1995. Prives served as Chair of that department between 2000 and 2004. Since the late 1980’s her work has focused on the p53 tumor suppressor protein, the product of the most frequently mutated gene in human cancers. Her work has focused on the structure and functional analysis of the p53 protein especially as it relates to its roles as a transcriptional activator. Similarly she has examined how cancer related mutant forms of p53 regulate tumorigenesis. Work from her group has also illuminated the functions of the p53 negative regulators, Mdm2 and MdmX.

Prives has served as Chair of both the Experimental Virology and the Cell and Molecular Pathology Study Sections of the NIH and was a member of the NCI Intramural Scientific Advisory Board. She was also a member of the Advisory Boards of the Dana-Farber Cancer Center, the Memorial Sloan Kettering Cancer Center and the Massachusetts General Cancer Center as well as the American Association for Cancer Research. Prives has received several honors including being named an American Cancer Society Research Professor, election to the American Academy of Arts and Sciences, the Institute of Medicine and the National Academy of Sciences. She has received awards and lectureships including the NCI Rosalind E Franklin Award for Women in Science and the AACR-Women in Cancer Research Charlotte Friend Memorial Lectureship Award. Most recently she was awarded an honorary doctorate from McGill University, her alma mater.

Patrick Sullivan is a passionate childhood cancer advocate, Chairman of the Board of Coast to Coast Against Cancer Foundation, the President and a founder of the Team Finn Foundation, and Co-Founder of Ac2orn. Patrick became an advocate after his twin son Finn was diagnosed with Rhabdomyosarcoma in 2007 and he heard the word “incurable” for the first time. His desire to make a change in cancer research is in part an effort to pay an un-payable debt to his son Finn and to change the stories of other Finn’s.

Patrick participates in several national and international initiatives that include member of the AACR Pediatric Cancer Working Group, lead Patient Advocate on the St. Baldrick’s – Stand-Up to Cancer Pediatric Cancer Dream Team, Patient Advocate on the SU2C Canada Cancer Stem Cell Dream Team, Director on the Canadian Cancer Research Alliance, Co-Lead of the Terry Fox Research Profyle initiative, member of the CTCG Lay Representative Committee and Chair of the Bio-CanRX Cancer Stakeholder Alliance.

By profession, Patrick is a securities and corporate-commercial litigator and one of the founding partners of Taylor Veinotte Sullivan. Patrick is the proud father of three remarkable children, Baird, Sarah and Finn and would do almost anything for the simple pleasure of holding Finn’s hand again.

John D. Carpten, PhD, currently serves as Professor and Chair for the Department of Translational Genomics, and Director of the Institute for Translational Genomics, the Keck School of Medicine, University of Southern California, Los Angeles, CA. Previously he was Professor and Deputy Director of Basic Sciences, Translational Genomics Research Institute, Phoenix, AZ.

Carpten’s research background spans a very broad range of topics including work in germline genetics, tumor genome analysis, cancer cell biology, and health disparities. His research program centers around the development and application of cutting edge genomic technologies and bioinformatics analysis in search of germ-line and somatic alterations that are associated with cancer risk and tumor biology, respectively. His work spans many of the known cancer types including but not limited to prostate cancer, breast cancer, colon cancer, brain cancer, multiple myeloma, and pediatric cancers.

Moreover, Carpten has an intense focus on understanding the role of biology in disparate cancer incidence and mortality rates seem among underrepresented populations. He was names a Science Trailblazer by Spectrum Magazine in 2006, and was awarded Susan G. Komen Distinguished Lectureship on the Science of Cancer Health Disparities in 2014 for his untiring work in ensuring that all people are equally represented in science and innovative healthcare. More recently, Carpten was awarded the Jane Cooke Wright Memorial Lectureship by Minorities in Cancer Research of the American Association for Cancer Research (AACR) for his outstanding work in cancer disparities and his efforts to develop the careers of minority scientists.

Carpten has participated in numerous evaluative positions throughout his career. He served as a Senior Editor for Cancer Research, a journal of the AACR, and as an ad hoc editor for a number of other high impact journals. He has served on and chaired several NIH study sections, and is currently a permanent member of the NCI Board of Scientific Counselors. He also sits on one of the NIH Director’s Special Advisory committees. He served as Program Committee Chairperson for the AACR 2019 Annual Meeting in Atlanta and co-chaired the AACR inaugural Special Conference on the Science of Cancer Health Disparities.